文献速递慢性肾脏病

肥胖与代谢异常与CKD进展的关联

Obesity, Metabolic Abnormality, and Progression of CKD.
PubMed 文献 · Am J Kidney Dis · 2018-05-02

基于韩国KNOW-CKD前瞻性队列1940例患者,平均随访3.1年,主要终点为eGFR下降50%或终末期肾病。多变量分析显示,肥胖和代谢异常分别与肾脏不良结局风险增加1.41倍和1.38倍相关。值得注意的是,无代谢异常的肥胖患者CKD进展风险也升高(HR 1.97)。

要点

  • 肥胖(BMI≥25kg/m2)与代谢异常均独立增加CKD进展风险。
  • 无代谢异常的肥胖患者CKD进展风险同样升高(HR 1.97)。
  • 肥胖合并代谢异常者CKD进展风险增加(HR 1.53)。

核心结论

  • 肥胖和代谢异常均与CKD进展风险显著增加相关。
  • 无代谢异常的肥胖患者CKD进展风险也升高。

研究设计与样本

  • 前瞻性观察性队列研究,纳入韩国KNOW-CKD队列1940例患者。
  • 肥胖定义为BMI≥25kg/m2,代谢异常定义为5项组分中≥3项。
  • 主要终点为eGFR较基线下降50%或终末期肾病。

主要发现

  • 平均随访3.1年,395例(20.4%)发生主要终点事件。
  • 肥胖与肾脏不良结局风险增加1.41倍相关(95%CI 1.08-1.83;P=0.01)。
  • 代谢异常与肾脏不良结局风险增加1.38倍相关(95%CI 1.03-1.85;P=0.03)。
  • 肥胖合并代谢异常者CKD进展风险增加(HR 1.53;P=0.03)。
  • 无代谢异常的肥胖者CKD进展风险也升高(HR 1.97;P=0.01)。

关键数值与推荐

  • 肥胖:BMI≥25kg/m2。
  • 代谢异常:高血压、空腹血糖>125mg/dL或2型糖尿病、甘油三酯>150mg/dL或使用降脂药、HDL-C男性≤40mg/dL女性≤50mg/dL、hs-CRP>1mg/L,5项中≥3项。

临床怎么用

  • 对CKD患者应同时评估肥胖和代谢异常,二者均提示进展风险升高。
  • 无代谢异常的肥胖CKD患者也需关注肾脏进展风险。

局限性

  • 观察性研究,检测心血管疾病结局的效能有限,存在未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Recent studies have yielded conflicting findings on the association between obesity and progression of chronic kidney disease (CKD). Few studies have evaluated whether metabolic abnormalities may accelerate the rate of progression of CKD. STUDY DESIGN: Prospective observational cohort study. SETTING & PARTICIPANTS: 1,940 participants from the Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD) PREDICTORS: Obesity and metabolic abnormality. Obesity was defined as body mass index ≥ 25kg/m2. Metabolic abnormality was defined as the presence of 3 or more of the following 5 components: hypertension, fasting glucose level > 125mg/dL or the presence of type 2 diabetes, triglyceride level > 150mg/dL or use of lipid-lowering drugs, high-density lipoprotein cholesterol level ≤ 40mg/dL in men and ≤ 50mg/dL in women, and high-sensitivity C-reactive protein level > 1mg/L. OUTCOME: A composite of a 50% decline in estimated glomerular filtration rate from the baseline value or end-stage kidney disease. ANALYTIC APPROACH: Multivariable cause-specific hazards models implemented to assess the association between obesity, metabolic abnormality, and CKD progression. RESULTS: During a mean follow-up of 3.1 years, the primary outcome occurred in 395 (20.4%) patients. In multivariable analyses, after adjustment for confounding factors, obesity and metabolic abnormality were significantly associated with 1.41-fold (95% CI, 1.08-1.83; P=0.01) and 1.38-fold (95% CI, 1.03-1.85; P=0.03) increased risk for adverse renal outcomes, respectively. Patients were categorized into 4 groups depending on the presence of obesity and metabolic abnormality. Compared with those with neither obesity nor metabolic abnormality, those with obesity and metabolic abnormality had a greater risk for CKD progression (HR, 1.53; P=0.03). Those with obesity without metabolic abnormality also had a higher rate of CKD progression (HR, 1.97; P=0.01). LIMITATIONS: Observational study, limited power to detect cardiovascular disease outcomes, unmeasured confounders. CONCLUSIONS: Both metabolic abnormality and obesity are associated with a significantly increased risk for CKD progression. Notably, obese patients without metabolic abnormality also have an elevated risk for CKD progression.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Yun HR, Kim H, Park JT, et al. Obesity, Metabolic Abnormality, and Progression of CKD. Am J Kidney Dis. 2018. PMID: 29728317. doi:10.1053/j.ajkd.2018.02.362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。